Search the Newsreel

uniQure N.V. to announce Q2 2026 financial results on July 29

uniQure N.V. (NASDAQ: QURE) is scheduled to release its second-quarter 2026 financial results before market open on Wednesday, July 29, 2026, followed by a conference call at 8:30 a.m. ET. The company will discuss financial outcomes and operational updates regarding its gene therapy pipeline, …

uniQure sets July 29 webcast after Q2 financial results

Aberdeen Group plc (QURE) discloses 2.85M-share, 4.52% holding in uniQure

Aberdeen Group plc and its subsidiary abrdn Inc. have disclosed an updated passive ownership stake in uniQure N.V. (QURE) through an Amendment No. 4 to Schedule 13G. As of June 30, 2026, they beneficially own 2,848,117 ordinary shares, which constitutes 4.52% of the outstanding …

uniQure NV | 144: Notice of proposed sale of securities pursuant to Rule 144

This document is a formal Notice of Proposed Sale of Securities pursuant to Rule 144 for uniQure NV. It indicates an intention to sell securities under specific conditions designed to ensure liquidity for restricted and control securities. Further details regarding the nature and volume …

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

uniQure (QURE) is evolving beyond its single program gene therapy, Hemgenix, by focusing on faster regulatory pathways, streamlining its operations, and expanding into rare neurological diseases. The company's Huntington's disease gene therapy, AMT-130, has received multiple FDA designations, suggesting a quicker path to approval, …

UniQure (QURE) now trades above golden cross: Time to buy?

This article discusses the recent technical indicator of UniQure (QURE) trading above its golden cross. It suggests that this development could be a strong signal for investors to consider buying the stock, indicating potential upward momentum. The content likely examines the implications of this …

QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway

uniQure (QURE) is primarily driven by its gene therapy candidate, AMT-130, for Huntington’s disease, with a potential biologics license application submission in Q3 2026 and a cash runway extending into late 2029. Recent positive feedback from the FDA on a clearer regulatory path for …

Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?

uniQure N.V. (QURE) stock has seen a significant rally due to renewed investor interest in its lead gene therapy candidate, AMT-130, for Huntington's disease. Despite positive earnings surprises and a strong cash position that funds operations into 2029, the stock's valuation is considered rich, …

JPMorgan discloses 7% uniQure (QURE) stake of 4,866,211 shares

JPMorgan Chase & Co. has filed a Schedule 13G, disclosing a beneficial ownership of 4,866,211 Ordinary Shares in uniQure N.V. (QURE), which represents a 7.0% stake in the company. JPMorgan holds sole voting power over 4,598,521 shares and sole dispositive power over 4,866,201 shares. …

Price to earnings forward of uniQure N.V. – NASDAQ:QURE

uniQure (NASDAQ: QURE) files Rule 144 resale notice listing recent insider sales

QURE Stock Soars As FDA Boosts Gene Therapy Outlook

Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message

UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play

UNIQURE ($QURE) Releases Q4 2025 Earnings | QURE Stock News

uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges